Skinny Label Limits: Supreme Court Denies Norwich Bid For US Xifaxan Reprieve

 
• By Dave Wallace

Removing the patent-protected indication from the label of Norwich Pharmaceuticals's proposed generic for Xifaxan did not convince the US Supreme Court to hear its petition to review a case from Bausch Health that blocked approval until 2029.

The Supreme Court denied Norwich’s request to review its case. (Shutterstock)

More from Generics

More from Patents